APOL1 Kidney Risk Variants and Proteomics
- 1 May 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 17 (5) , 684-692
Abstract
Background and objectives: The APOL1 risk variants (G1 and G2) are associated with kidney disease among Black adults, but the clinical presentation is heterogeneous. In mouse models and cell systems, increased gene expression of G1 and G2 confers cytotoxicity. How APOL1 risk variants relate to the circulating proteome warrants further investigation. Design, setting, participants, & measurements: Among 461 African American Study of Kidney Disease and Hypertension (AASK) participants (mean age: 54 years; 41% women; mean GFR: 46 ml/min per 1.73 m2), we evaluated associations of APOL1 risk variants with 6790 serum proteins (measured via SOMAscan) using linear regression models. Covariates included age, sex, percentage of European ancestry, and protein principal components 1–5. Associated proteins were then evaluated as mediators of APOL1-associated risk for kidney failure. Findings were replicated among 875 Atherosclerosis Risk in Communities (ARIC) study Black participants (mean age: 75 years; 66% women; mean eGFR: 67 ml/min per 1.73 m2). Results: In the AASK study, having two (versus zero or one) APOL1 risk alleles was associated with lower serum levels of APOL1 (P=3.11E-13; P=3.12E-06 [two aptamers]), APOL2 (P=1.45E-10), CLSTN2 (P=2.66E-06), MMP-2 (P=2.96E-06), SPOCK2 (P=2.57E-05), and TIMP-2 (P=2.98E-05) proteins. In the ARIC study, APOL1 risk alleles were associated with APOL1 (P=1.28E-11); MMP-2 (P=0.004) and TIMP-2 (P=0.007) were associated only in an additive model, and APOL2 was not available. APOL1 high-risk status was associated with a 1.6-fold greater risk of kidney failure in the AASK study; none of the identified proteins mediated this association. APOL1 protein levels were not associated with kidney failure in either cohort. Conclusions: APOL1 risk variants were strongly associated with lower circulating levels of APOL1 and other proteins, but none mediated the APOL1-associated risk for kidney failure. APOL1 protein level was also not associated with kidney failure.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (K08DK117068, P30DK079310, R01DK108803, R01DK24399)
- National Heart, Lung, and Blood Institute (K24HL155861)
This publication has 30 references indexed in Scilit:
- APOL1 Variants Associate with Increased Risk of CKD among African AmericansJournal of the American Society of Nephrology, 2013
- Involvement of matrix metalloproteinase-2 in the development of renal interstitial fibrosis in mouse obstructive nephropathyLaboratory Investigation, 2012
- The APOL1 Genotype of African American Kidney Transplant Recipients Does Not Impact 5-Year Allograft SurvivalAmerican Journal of Transplantation, 2012
- APOL1 Localization in Normal Kidney and Nondiabetic Kidney DiseaseJournal of the American Society of Nephrology, 2011
- Aptamer-Based Multiplexed Proteomic Technology for Biomarker DiscoveryPLOS ONE, 2010
- Intensive Blood-Pressure Control in Hypertensive Chronic Kidney DiseaseNew England Journal of Medicine, 2010
- Association of Trypanolytic ApoL1 Variants with Kidney Disease in African AmericansScience, 2010
- Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 geneHuman Genetics, 2010
- Effect of Blood Pressure Lowering and Antihypertensive Drug Class on Progression of Hypertensive Kidney DiseaseResults From the AASK TrialJAMA, 2002
- The Calsyntenins—A Family of Postsynaptic Membrane Proteins with Distinct Neuronal Expression PatternsMolecular and Cellular Neuroscience, 2002